Biosimilars in Oncology

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Recent trends in drug development have seen the price of new medicines continually increase, and there is a need for cheaper medicines to achieve global sustainable healthcare. Biologic drugs are some of the most expensive medicines to develop, as they are large complex molecules. Biosimilars are highly similar to approved biologic drugs, with no clinically relevant differences, and aim to achieve the same clinical results at a lower price than their originator molecules. This is a key way in which the cost-savings required to promote sustainability can be achieved.
In oncology, biosimilar versions of six biologic drugs are now available. The EMA has pioneered regulatory acceptance of biosimilars, and has approved many more biosimilars than the FDA. Beyond the major markets of the US and 5EU (France, Germany, Italy, Spain and UK), two emerging markets are important in the oncology biosimilars landscape: India, with the most approved biosimilars globally, and South Korea, home to major biosimilar developer Celltrion.
This report provides an assessment of the current oncology biosimilars landscape in the 9MM (US, 5EU, Japan, India and South Korea), including market potential, current and expected use of biosimilars, clinical and commercial concepts, regulatory pathways, important indications, and an overview of leading and emerging developers.


GlobalData’s Biosimilars in Oncology report combines primary research from oncology experts and a high prescribing physicians’ survey with in-house analyst expertise to provide an assessment of the marketplace.

Components of the slide deck include primary and secondary research:

• Quotes from 11 US-, 5EU-, Japan-, and India-based experts, including Key Opinion Leaders (KOLs) and payers

• Quantitative survey information from 107 US-, 5EU-, India-, South Korea-based high-prescribing physicians

• Summary of key clinical and commercial concepts for biosimilars

• Overview of biosimilar regulatory pathways across key markets

• Analysis of potential of each key biosimilars market

• Outline of important indications for oncology biosimilars

• Review of key biosimilar developers and their portfolios

• Insight from GlobalData’s specialist oncology analysts

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of the oncology biosimilar landscape and its key players.

Organize your efforts by understanding the market potential and current regulatory outlook shaping the oncology biosimilars landscape in key markets.

Develop strategies by understanding expert and high prescriber perceptions of biosimilars, and drivers for current use patterns and expected changes in use.

Accord Healthcare
Alkem Laboratories
Archigen Biotech
Boehringer Ingelheim
Cadila Healthcare
Centus Biotherapeutics
Cinfa Biotech
Claris Lifesciences
Coherus BioSciences
CT Arzneimittel
Daewoong Pharmaceutical
Daiichi Sankyo
Dr. Reddy’s Laboratories
Emcure Pharmaceuticals
Fuji Pharma
Gedeon Richter
Glenmark Pharmaceuticals
Hetero Drugs
Intas Pharmaceuticals
Kissei Pharmaceutical
Kyowa Hakko Kirin
Medice Arzneimittel Putter
Meiji Seika Pharma
Merck & Co
Mochida Pharmaceutical
Nippon Kayaku
Panacea Biotec
Prestige BioPharma
Prolong Pharmaceuticals
Reliance Life Sciences
Samsung Bioepis
Synthon Holdings
Tanvex BioPharma
Torrent Pharmaceuticals
Zenotech Laboratories

Table of Contents

Table of Content (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Related Reports

1.3 Upcoming Related Reports

2 Executive Summary

3 Introduction

3.1 What is a Biosimilar?

3.2 Timeline of Oncology Biosimilar Development by Country in the 7MM

3.3 Timeline of Oncology Biosimilar Approvals in India and South Korea

4 Biosimilars – Key Clinical and Commercial Concepts

4.1 Differences Between Generics and Biosimilars

4.2 Differences Between Biosimilarity and Interchangeability

4.3 Pricing Issues for Biosimilars

5 Biosimilar Regulatory Pathways Across Geographies

5.1 Biosimilar Development Overview

5.2 US Biosimilar Regulatory Pathway

5.3 EU Biosimilar Regulatory Pathway

5.4 Japan Biosimilar Regulatory Pathway

5.5 South Korea Biosimilar Regulatory Pathway

5.6 India Biosimilar Regulatory Pathway

6 Biosimilar Market Potential in the 9MM

6.1 US Biosimilar Market Potential

6.2 5EU Biosimilar Market Potential

6.3 Japan Biosimilar Market Potential

6.4 South Korea Biosimilar Market Potential

6.5 India Biosimilar Market Potential

7 Important Indications for Oncology Biosimilars

7.1 Biologic Use Across Oncology

7.2 HER2+ Breast Cancer

7.3 Colorectal Cancer

7.4 Hematological Cancers – NHL and CLL

7.5 Supportive Care in Oncology

8 Major Players and Emerging Players

8.1 Importance of Manufacturer Reputation

8.2 Sandoz as a Major Player

8.3 Celltrion as a Major Player

8.4 Amgen as a Major Player

8.5 Mylan and Biocon as Major Players

8.6 Pfizer and Boehringer Ingelheim as Emerging Players

9 Current Market Dynamics and Future Outlook: Results from a High-Prescriber Survey

9.1 Current Availability of Approved Biosimilars

9.2 Patterns of Use of Oncology Biosimilars

9.3 Substitution Rules by Country

9.4 Pricing Regulations for Biosimilars by Country

9.5 Desired Discounts for Oncology Biosimilars

9.6 Expected Changes in Prescription Patterns in the Next Five Years

9.7 Important Initiatives to Encourage Future Use of Biosimilars

10 Appendix

10.1 Primary Research

10. 2 Sources

10.3 About the Authors

10.4 About GlobalData

10.5 Contact Us

10.6 Disclaimer

Frequently asked questions

Biosimilars in Oncology thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Biosimilars in Oncology was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Biosimilars in Oncology in real time.

  • Access a live Biosimilars in Oncology dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.